Business
Results for the six months ended 30 June 2024
Results for the six months ended 30 June 2024.
About this update from Croda International Plc
[{"type":"text","content":"\n\n \n\n\n\nPress Release \n30 July 2024\n \nResults for the six months ended 30 June 2024\nGroup performance in line with expectations reflecting more stable market conditions and operational progress\nCroda International Plc (\"Croda\" or the \"Group\") announces its half year results for the six months ended 30 June 2024.\nHighlights\n\n\n\n\n\n\n\nStatutory results (IFRS)\n\n\nAdjusted results\n\n\n\n\nHalf year ended 30 June\n\n\nH124\n\n\nH123\n\n\nchange\n\n\nH124\n\n\nH123\n\n\nConstant\n currency change\n\n\n change\n\n\n\n\nSales (£m)\n\n\n815.9\n\n\n880.9\n\n\n(7.4)%\n\n\n815.9\n\n\n880.9\n\n\n(4.4)%\n\n\n(7.4)%\n\n\n\n\nOperating profit (£m)\n\n\n114.4\n\n\n130.2\n\n\n(12.1)%\n\n\n135.6\n\n\n175.8\n\n\n(18.9)%\n\n\n(22.9)%\n\n\n\n\nOperating margin (%)\n\n\n\n\n\n\n\n\n\n\n\n16.6\n\n\n20.0\n\n\n-\n\n\n(3.4)ppts\n\n\n\n\nProfit before tax (£m)\n\n\n106.1\n\n\n128.7\n\n\n(17.6)%\n\n\n127.3\n\n\n174.3\n\n\n(23.2)%\n\n\n(27.0)%\n\n\n\n\nBasic earnings per share (p)\n\n\n57.2\n\n\n63.1\n\n\n(9.4)%\n\n\n68.8\n\n\n92.9\n\n\n-\n\n\n(25.9)%\n\n\n\n\nOrdinary dividend per share (p)\n\n\n47.0\n\n\n47.0\n\n\n0.0%\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFree cash flow (£m)\n\n\n\n\n\n\n\n\n\n\n\n122.7\n\n\n72.8*\n\n\n-\n\n\n68.5%\n\n\n\n\nNet debt (£m)\n\n\n\n\n\n\n\n\n\n\n\n507.9\n\n\n349.3\n\n\n-\n\n\n(45.4)%\n\n\n\n\n \n \n \nSales growth %\n\n\nChange\nv H123\n\n\nChange\nv H123\nconstant currency\n\n\nChange\nv H223\n ex CV191\n\n\n \n\n\n\n\n\nConsumer Care\n\n\n3%\n\n\n6%\n\n\n9%\n\n\n \n\n\n\n\n\nLife Sciences\n\n\n(19)%\n\n\n\n(16)%\n\n\n\n(2)%\n\n\n \n\n\n\n\n\nIndustrial Specialties\n\n\n(17)%\n\n\n\n(14)%\n\n\n\n 21%\n\n\n \n\n\n\n\n\nGroup\n\n\n(7)%\n\n\n \n (4)%\n\n\n \n 7%\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n% changes are comparisons with reported H123 results unless stated. For a reconciliation of % changes compared with H223 results see Sector performance section. 1Life Sciences and Group sales exclude £48m of lipid sales for CV19 vaccine applications in Q4 2023. Where explicitly stated, constant currency comparisons remove the impact of currency translation into Sterling, the Group's reporting currency. *H123 free cash flow has been restated in li...